These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8021737)

  • 1. Phase I study of oral etoposide in children with refractory solid tumors.
    Mathew P; Ribeiro RC; Sonnichsen D; Relling M; Pratt C; Mahmoud H; Bowman L; Meyer W; Avery L; Crist W
    J Clin Oncol; 1994 Jul; 12(7):1452-7. PubMed ID: 8021737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
    Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
    Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).
    Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR
    Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
    Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
    Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
    Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
    Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
    Blaney S; Berg SL; Pratt C; Weitman S; Sullivan J; Luchtman-Jones L; Bernstein M
    Clin Cancer Res; 2001 Jan; 7(1):32-7. PubMed ID: 11205914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of recurrent medulloblastoma to low-dose oral etoposide.
    Ashley DM; Meier L; Kerby T; Zalduondo FM; Friedman HS; Gajjar A; Kun L; Duffner PK; Smith S; Longee D
    J Clin Oncol; 1996 Jun; 14(6):1922-7. PubMed ID: 8656261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
    Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
    Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
    Pein F; Pinkerton R; Berthaud P; Pritchard-Jones K; Dick G; Vassal G
    Eur J Cancer; 2007 Sep; 43(14):2074-81. PubMed ID: 17716890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
    Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G
    Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA; Krailo M; Reid JM; Ruben SL; Ames MM; Owen W; Reaman G;
    J Clin Oncol; 2005 Dec; 23(36):9179-86. PubMed ID: 16361620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.
    Bowers DC; Aquino VM; Leavey PJ; Bash RO; Journeycake JM; Tomlinson G; Mulne AF; Haynes HJ; Winick NJ
    Pediatr Blood Cancer; 2004 Jan; 42(1):93-8. PubMed ID: 14752800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
    ; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
    J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic daily administration of oral etoposide--a phase I trial.
    Hainsworth JD; Johnson DH; Frazier SR; Greco FA
    J Clin Oncol; 1989 Mar; 7(3):396-401. PubMed ID: 2918334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.